学术周报 · IF≥10
肾内科领域文献阅读汇编
2026年第39周 (2026-09-23) | PubMed (NLM) · DeepSeek 中英双语
数据来源: PubMed E-utilities · 影响因子筛选≥10 · 完整摘要不截断
数据来源: PubMed E-utilities · 影响因子筛选≥10 · 完整摘要不截断
★本周 Top 10 高影响力文献
Ŧ期刊分布统计
| 期刊 | 篇数 | IF |
|---|---|---|
| Kidney international | 6 | IF 21.8 |
| European journal of preventive cardiology | 1 | IF 10.0 |
| Advanced healthcare materials | 1 | IF 11.0 |
| Pharmacological research | 1 | IF 12.2 |
| Intensive care medicine | 1 | IF 22.0 |
| ACS sensors | 1 | IF 10.9 |
| Circulation | 1 | IF 41.3 |
1慢性肾脏病 CKD (6篇)
临床研究 (4篇)
Congenital anomalies of the kidney and urinary tract (CAKUT) are a heterogeneous group of structural defects that arise from disordered nephrogenesis. CAKUT accounts for 20%-30% of all prenatal anomalies, with a pooled birth prevalence of 3.83 per 1000. The pathogenesis reflects disrupted ureteric bud-metanephric mesenchyme signalling and early transcriptional programs. Genetic disorders underlie approximately one-fifth of cases, with monogenic causes (notably HNF1β and PAX2) and copy number variants being particularly prevalent in syndromic presentations. The broad phenotypic expression underscores the value of genetic testing in cases of severe or syndromic disease, familial dysplasia, bilateral dysplasia (often cystic), and idiopathic chronic kidney disease/kidney replacement therapy (KRT). We will focus on two defects, being the most common causes of pediatric CKD: kidney dysplasia/hypoplasia and lower urinary tract obstruction. Chronic kidney damage associated with CAKUT progresses slowly, while the peak need for KRT occurs in adolescence, the average commencement is around 31 years of age. These patients carry a heightened risk of cardiovascular and metabolic disease, neurocognitive impairment and a small increased risk of malignancy. A life-course model of care, integrating targeted genetic diagnosis with proactive management of CKD and its extrarenal sequelae, is essential to improve outcomes.
中文摘要:先天性肾脏和泌尿道畸形(CAKUT)是一组异质性结构缺陷,源于肾发生过程紊乱。CAKUT占所有产前畸形的20%-30%,合并出生患病率为3.83/1000。其发病机制反映了输尿管芽-后肾间充质信号传导以及早期转录程序受到破坏。遗传性疾病约占病例的五分之一,其中单基因病因(尤其是HNF1β和PAX2)和拷贝数变异在综合征型表现中尤为常见。广泛的表型表达凸显了在严重或综合征型疾病、家族性发育不良、双侧发育不良(常为囊性)以及特发性慢性肾脏病/肾脏替代治疗(KRT)病例中进行基因检测的价值。我们将重点关注两种缺陷,它们是儿童慢性肾脏病最常见的原因:肾发育不良/肾发育不全和下尿路梗阻。与CAKUT相关的慢性肾损伤进展缓慢,而KRT需求高峰出现在青春期,平均开始时间约为31岁。这些患者心血管和代谢疾病、神经认知损害的风险升高,恶性肿瘤风险略有增加。整合针对性基因诊断与对CKD及其肾外后遗症的主动管理,并采用贯穿生命周期的照护模式,对于改善结局至关重要。
Lower potassium intake is associated with an increased risk of cardiovascular disease (CVD) in the general population, with observed sex differences. However, few studies have investigated the relationship between potassium intake and CVD in patients with chronic kidney disease (CKD), and sex-specific differences have not been well examined. A total of 4314 patients aged 18 years or older in Japan were prospectively followed for 5 years using data from the Fukuoka Kidney disease Registry study. The patients were divided into sex-specific quartiles according to the estimated potassium intake, which was calculated using the Tanaka formula from spot urine samples. The primary outcome was the occurrence of CVD events. Cox proportional hazards models were used to evaluate the association between the estimated potassium intake and CVD in the overall cohort with stratification by sex. Over a 5-year follow-up, 431 patients developed CVD [292 (12.1%) men and 139 (7.3%) women]. In the overall cohort, patients in the lowest quartile of estimated potassium intake tended to have a higher hazard ratio (HR) for CVD than those in the highest quartile [HR (95% CI), 1.41 (0.97-2.03)]. A significant interaction between sex and potassium intake was observed (P < 0.001). In sex-stratified analyses, lower potassium intake was significantly associated with an increased risk of CVD in women [HR (95% CI): men, 0.98 (0.63-1.53); women, 2.97 (1.44-6.10)]. Lower estimated potassium intake is associated with a higher risk of CVD in patients with CKD, with a particularly strong association in women.
中文摘要:较低的钾摄入量与一般人群中心血管疾病风险增加相关,并观察到性别差异。然而,少有研究探讨慢性肾脏病患者钾摄入量与心血管疾病之间的关系,性别特异性差异也尚未得到充分研究。本研究利用福冈肾病登记研究的数据,前瞻性随访了日本4314例年龄18岁及以上患者5年。根据估计钾摄入量将患者按性别特异性四分位数分组,估计钾摄入量采用Tanaka公式通过点尿样本计算。主要结局为心血管疾病事件的发生。采用Cox比例风险模型评估整体队列中估计钾摄入量与心血管疾病之间的关联,并按性别分层。在5年随访期间,431例患者发生心血管疾病,其中男性292例(12.1%),女性139例(7.3%)。在整体队列中,估计钾摄入量最低四分位组患者的心血管疾病风险比趋于高于最高四分位组,风险比为1.41(95% CI 0.97-2.03)。观察到性别与钾摄入量之间存在显著交互作用(P < 0.001)。在性别分层分析中,较低钾摄入量与女性心血管疾病风险增加显著相关,风险比分别为男性0.98(95% CI 0.63-1.53),女性2.97(95% CI 1.44-6.10)。较低的估计钾摄入量与慢性肾脏病患者较高的心血管疾病风险相关,且在女性中关联尤其强。
Acute impairment of kidney function after cardiac surgery is common and associated with an increased morbidity and mortality. Ilofotase alfa has demonstrated potential to attenuate renal injury through its immunomodulatory effects. We evaluated the safety and efficacy of ilofotase alfa in preventing renal functional impairment in cardiac surgery patients. This phase 2, multi-center, randomized, double-blinded, placebo-controlled trial employing a two-arm, parallel-group design randomized adult patients at a high risk of renal functional impairment after on-pump cardiac surgery. Patients with a pre-existent estimated glomerular filtration rate of 25-65 ml/min/1.73m2 scheduled to undergo complex cardiac surgery were eligible. Patients received two intravenous doses (128 mg) of ilofotase alfa or placebo perioperatively. The primary endpoint was the ratio between the highest serum creatinine levels within five days postoperative relative to the pre-operative level (sCrRatio). The secondary endpoint was major adverse kidney events up to day 60 (MAKE60). In total, 244 patients were randomized of whom 204 received two doses and were included in the trial analysis: 109 patients were treated with ilofotase alfa and 95 received placebo. The mean±SD sCrRatio in the ilofotase alfa group was 1.21±0.42, compared to 1.27±0.50 for placebo (p=0.31). MAKE60 incidence was 15.9% in the ilofotase alfa group and 15.4% in the placebo group (p=0.87). No safety concerns were raised. Administration of ilofotase alfa did not attenuate short- and longer-term renal function loss in patients at a high risk of renal functional impairment after on-pump cardiac surgery. No safety concerns of ilofotase alfa emerged. EUCT Number: 2023-505859-45 US IND Number: 117 605 ClinicalTrials.gov ID: NCT06168799.
中文摘要:心脏手术后急性肾功能损害常见,并与发病率和死亡率增加相关。Ilofotase alfa 已显示出通过免疫调节作用减轻肾损伤的潜力。我们评估了 ilofotase alfa 在心脏手术患者中预防肾功能损害的安全性和有效性。这项2期、多中心、随机、双盲、安慰剂对照试验采用双臂平行组设计,随机纳入体外循环心脏手术后肾功能损害高风险的成年患者。既往估算肾小球滤过率为25-65 ml/min/1.73m2并计划接受复杂心脏手术的患者符合入组条件。患者围手术期接受两剂静脉注射 ilofotase alfa(128 mg)或安慰剂。主要终点为术后5天内最高血清肌酐水平相对于术前水平的比值(sCrRatio)。次要终点为截至第60天的主要不良肾脏事件(MAKE60)。共随机244例患者,其中204例接受两剂并被纳入试验分析:109例接受 ilofotase alfa 治疗,95例接受安慰剂。Ilofotase alfa 组的平均±标准差 sCrRatio 为1.21±0.42,而安慰剂组为1.27±0.50(p=0.31)。MAKE60发生率在 ilofotase alfa 组为15.9%,安慰剂组为15.4%(p=0.87)。未发现安全性问题。在接受体外循环心脏手术后肾功能损害高风险患者中,给予 ilofotase alfa 并未减轻短期和较长期的肾功能丧失。Ilofotase alfa 未出现安全性问题。EUCT编号:2023-505859-45,美国IND编号:117605,ClinicalTrials.gov ID:NCT06168799。
Chronic kidney disease is a global epidemic affecting ≈10% of adults worldwide. Women have a higher prevalence of chronic kidney disease than men yet are less likely to progress to kidney failure, to initiate dialysis, or to receive a kidney transplantation, underscoring the influence of biological sex on chronic kidney disease development, progression, treatment response, and outcomes. Women may also respond differently from men to pharmacological therapies, but they remain underrepresented in clinical trials, limiting the evidence base for sex-specific kidney care. Preclinical evidence implicates a role for estrogen receptor signaling in renal physiology and pathophysiology. Women with chronic kidney disease are at increased risk for adverse pregnancy outcomes and hypertensive disorders of pregnancy, and pregnancy complications can also increase future chronic kidney disease risk. Menopause and aging accelerate chronic kidney disease progression in women as a result of declining estradiol and shifts in kidney estrogen receptor profiles. Endocrine and metabolic disorders such as polycystic ovary syndrome increase susceptibility to chronic kidney disease. Family planning, prepregnancy counseling, and antenatal care are essential to support reproductive health in women with chronic kidney disease. Because chronic kidney disease and cardiovascular disease are tightly intertwined, chronic kidney disease is also a leading contributor to cardiovascular mortality in women. Advancing precision kidney medicine for women requires equitable access to kidney care, embedding assessment of reproductive health in chronic care, trial design with adequate power that includes both women and men, and mechanistic studies linking reproductive health to long-term cardiovascular disease and chronic kidney disease development and progression.
中文摘要:慢性肾脏病是一种全球性流行病,影响全球约10%的成年人。女性慢性肾脏病患病率高于男性,但进展为肾衰竭、开始透析或接受肾移植的可能性却更低,这凸显了生物学性别对慢性肾脏病发生、进展、治疗反应和结局的影响。女性对药物治疗的反应也可能与男性不同,但她们在临床试验中仍代表性不足,限制了性别特异性肾脏照护的证据基础。临床前证据提示,雌激素受体信号在肾脏生理和病理生理中发挥作用。患有慢性肾脏病的女性发生不良妊娠结局和妊娠期高血压疾病的风险增加,而妊娠并发症也可能增加未来慢性肾脏病风险。绝经和衰老会因雌二醇下降及肾脏雌激素受体谱改变而加速女性慢性肾脏病进展。内分泌和代谢性疾病,如多囊卵巢综合征,会增加慢性肾脏病易感性。计划生育、孕前咨询和产前保健对于支持慢性肾脏病女性的生殖健康至关重要。由于慢性肾脏病与心血管疾病紧密交织,慢性肾脏病也是女性心血管死亡的主要原因之一。推进女性精准肾脏医学需要公平获得肾脏照护,将生殖健康评估纳入慢性病照护,设计具有足够检验效能且同时纳入女性和男性的试验,并开展将生殖健康与长期心血管疾病及慢性肾脏病发生和进展联系起来的机制研究。
基础研究 (2篇)
Acute kidney injury (AKI) frequently progresses to chronic kidney disease (CKD) and is increasingly linked to significant remote neuropsychiatric sequelae. However, current therapeutic strategies usually lack renal targeting and, critically, neglect to address these systemic comorbidities, particularly the associated cognitive deficits and anxiety-like behaviors. In this study, we developed a biomimetic platform consisting of neutrophils loaded with superparamagnetic iron oxide nanoparticles encapsulating celastrol (termed NSPIOC), as an MRI-visible theranostic system for targeted renal therapy and simultaneous mitigation of associated neuropsychiatric impairments. Systemically administered NSPIOC leverage innate neutrophil chemotaxis to home toward renal inflammatory gradients. Upon infiltration, inflammation-triggered NETosis releases the cargo into vulnerable proximal tubules, while T2-weighted MRI enables real-time monitoring of neutrophil recruitment. Our results demonstrate that NSPIOC effectively restore renal function and inhibits the AKI-to-CKD transition. Importantly, our findings provide new evidence that renal-targeted intervention can alleviate AKI-induced cognitive deficits and anxiety-like behaviors. Mechanistically, restoring renal homeostasis prevents the pathological hyperactivation of glutamatergic neurons in the medial prefrontal cortex (mPFC). This biomimetic platform offers a holistic strategy for managing AKI by simultaneously addressing primary renal injury and remote neurological dysfunction, presenting a promising approach to systemic inflammatory complications.
中文摘要:急性肾损伤(AKI)常进展为慢性肾脏病(CKD),并日益被认为与显著的远端神经精神后遗症相关。然而,当前治疗策略通常缺乏肾脏靶向性,且关键的是忽视了这些全身性共病,尤其是相关的认知缺陷和焦虑样行为。在本研究中,我们开发了一种仿生平台,由负载包裹雷公藤红素的超顺磁性氧化铁纳米颗粒的中性粒细胞组成(称为NSPIOC),作为一种MRI可见的诊疗一体化系统,用于靶向肾脏治疗并同时减轻相关的神经精神损伤。全身给药后,NSPIOC利用中性粒细胞固有的趋化性向肾脏炎症梯度归巢。浸润后,炎症触发的NETosis将载荷释放到易损的近端小管,同时T2加权MRI可实时监测中性粒细胞募集。我们的结果表明,NSPIOC有效恢复肾功能并抑制AKI向CKD的转变。重要的是,我们的发现提供了新证据,表明肾脏靶向干预可以缓解AKI诱导的认知缺陷和焦虑样行为。机制上,恢复肾脏稳态可防止内侧前额叶皮层(mPFC)谷氨酸能神经元的病理性过度激活。该仿生平台通过同时处理原发性肾损伤和远端神经功能障碍,为管理AKI提供了一种整体策略,为系统性炎症并发症提供了一种有前景的方法。
Transdermal Creatinine Sensing in Live Animals with an Integrated Electrochemical Microneedle Patch.
Over 700 million people worldwide are estimated to suffer from chronic kidney disease (CKD), and creatinine is a critical biomarker for diagnosing and managing CKD. However, conventional detection relies on invasive blood sampling and time-consuming protocols and is susceptible to interference from endogenous substances and drugs. This highlights an urgent demand for convenient, non-invasive, and accurate monitoring strategies. This study presents a wearable electrochemical microneedle (MN) patch for minimally invasive and enzyme-free creatinine detection in transdermal interstitial fluid (ISF). Solid polycarbonate MNs are coated with conductive poly(3,4-ethylenedioxythiophene)-poly(styrenesulfonate). Copper ions (Cu2+) are immobilized on the surface through immersion treatment via coordination and electrostatic interactions, and a Nafion film is finally deposited to enhance stability and anti-interference ability. Quantitative detection is based on the peak current generated from the electrochemical oxidation of in situ formed Cu0 to Cu+, which subsequently undergoes specific coordination with creatinine. The patch exhibits a linear detection range of 5.00-300 μM for creatinine with a minimum detectable concentration of 1.00 μM. Benefiting from the strong coordination effect and permselectivity of Nafion, the patch shows high stability, excellent anti-interference ability, and reliable sensing performance. Integrated with a handheld potentiostat, this compact, lightweight, and low-cost sensor achieves real-time and accurate creatinine sensing within 90 s in ISF of live rabbit models, showing great promise for long-term home-based CKD management.
中文摘要:据估计,全球有超过7亿人患有慢性肾脏病(CKD),而肌酐是诊断和管理CKD的关键生物标志物。然而,传统检测依赖有创采血和耗时流程,且易受内源性物质和药物干扰。这凸显了对便捷、无创且准确监测策略的迫切需求。本研究提出一种可穿戴电化学微针(MN)贴片,用于在经皮间质液(ISF)中实现微创且无酶的肌酐检测。实心聚碳酸酯微针表面涂覆导电的聚(3,4-乙烯二氧噻吩)-聚(苯乙烯磺酸盐)。通过浸泡处理,铜离子(Cu2+)借助配位和静电作用固定在表面,最后沉积Nafion膜以增强稳定性和抗干扰能力。定量检测基于原位形成的Cu0电化学氧化为Cu+所产生的峰电流,随后Cu+与肌酐发生特异性配位。该贴片对肌酐的线性检测范围为5.00-300 μM,最低可检测浓度为1.00 μM。得益于强配位效应和Nafion的渗透选择性,该贴片表现出高稳定性、优异的抗干扰能力和可靠的传感性能。与手持恒电位仪集成后,这种紧凑、轻便且低成本的传感器可在活体兔模型的ISF中于90秒内实现实时、准确的肌酐传感,在长期居家CKD管理方面展现出巨大前景。
2肾移植 (2篇)
基础研究 (2篇)
Organ shortages remain a major limitation to kidney transplantation. Normothermic machine perfusion (NMP) is a technique to address this challenge by improving quality assessment and ex vivo organ preservation. However, the molecular state of the organ during NMP, and how it differs from in vivo physiology, remains poorly defined. To address this, we performed RNA sequencing and LC-MS/MS analyses of porcine and human kidneys during NMP. Cortical kidney tissue was collected from 60 porcine and 24 human donor kidneys at multiple time-points, including an in vivo baseline (porcine only), cold preservation, and four time points during NMP yielding 480 paired transcriptomic and proteomic profiles of donor kidneys. NMP triggered extensive, time-dependent transcriptional reprogramming (86% of genes differentially expressed) and more gradual proteomic alterations. NMP consistently activated inflammatory TNF-α/NF-κB signaling and suppressed oxidative phosphorylation, reflecting ischemia-reperfusion-like injury and impaired mitochondrial metabolism. Transcriptomic responses were highly similar between porcine and human kidneys, while proteomic responses showed greater inter-individual and interspecies variability. Warm ischemia induced persistent proteotoxic stress, characterized by activation of protein folding and chaperone pathways and sustained metabolic suppression. This suggests that the delayed and variable proteomic responses could result from stress-induced dysregulation of protein homeostasis. Additionally, conventional donor characteristics explained only a minor fraction of the change in biological behavior during NMP. The molecular profile of donor kidneys is extensively remodeled during NMP, creating an ex vivo state that diverges considerably from in vivo physiology. These molecular changes cannot be explained by differences in donor characteristics, indicating that other NMP-specific or injury-related factors dominate these deviating responses. Our findings deliver a high-resolution molecular map of kidneys during NMP and challenge the use of in vivo biomarkers for ex vivo assessment. Ex vivo specific responses should be considered when evaluating or resuscitating kidneys during perfusion.
中文摘要:器官短缺仍然是肾移植的主要限制。常温机械灌注(NMP)是一种通过改善质量评估和离体器官保存来应对这一挑战的技术。然而,NMP期间器官的分子状态及其与体内生理的差异仍不明确。为此,我们对NMP期间的猪和人类肾脏进行了RNA测序和LC-MS/MS分析。我们在多个时间点从60个猪供肾和24个人供肾中收集肾皮质组织,包括体内基线(仅猪)、冷保存以及NMP期间四个时间点,产生了480份供肾的配对转录组和蛋白质组图谱。NMP引发了广泛的、时间依赖性的转录重编程(86%的基因差异表达)以及更渐进的蛋白质组改变。NMP持续激活炎症性TNF-α/NF-κB信号并抑制氧化磷酸化,反映了缺血-再灌注样损伤和线粒体代谢受损。转录组反应在猪和人肾脏之间高度相似,而蛋白质组反应则表现出更大的个体间和种间变异性。温热缺血诱导持续的蛋白质毒性应激,其特征是蛋白质折叠和分子伴侣通路激活以及持续的代谢抑制。这表明延迟且多变的蛋白质组反应可能源于应激诱导的蛋白质稳态失调。此外,常规供体特征只能解释NMP期间生物学行为变化的一小部分。供肾的分子谱在NMP期间被广泛重塑,形成了一种与体内生理明显不同的离体状态。这些分子变化不能用供体特征的差异来解释,表明其他NMP特异性或损伤相关因素主导了这些偏离反应。我们的发现提供了NMP期间肾脏的高分辨率分子图谱,并挑战了将体内生物标志物用于离体评估的做法。在灌注期间评估或复苏肾脏时,应考虑离体特异性反应。
Delayed graft function after kidney transplant is associated with increased acute rejection rates and poorer long-term outcomes. It is significantly more prevalent in recipients of deceased than living donor kidneys due to increased ischemia-reperfusion injury associated with prolonged warm and cold ischemic times. Although specific immune populations are associated with ischemia-reperfusion injury and delayed graft function, the precise cellular circuits distinguishing deceased from living donor transplants, as well as the donor and recipient-derived immune programs involved in early immunological responses, have not been defined at cellular resolution. Using single-cell RNA-sequencing to examine this, we compared the pre-transplant immune landscape in 20 living and six deceased donor kidneys, with two additional deceased donor samples assessed by spatial transcriptomics. We then examined temporal immune changes using fixed single-cell RNA-profiling across eight matched pre- and post-transplant allograft pairs (16 samples total) from recipients of deceased kidney transplants who developed delayed graft function. Deceased donor allografts had donor-derived resident macrophages with reduced expression of chemokines, cytokines, and antigen presentation genes but increased autophagy and ubiquitination related transcripts. These macrophages persisted following transplantation and were spatially positioned to interact with multiple parenchymal populations. A loss of amphiregulin-expressing NK cells and CD8+ T cells expressing TIGIT and KLRC1 (NKG2A), accompanied by an enrichment of CD8+ T cells expressing KLRK1 (NKG2D) and a pro inflammatory signature were observed in both pre- and early post-transplant kidneys from deceased donors. Notably, a transcriptionally distinct, interferon-stimulated, recipient-derived macrophage population emerged early post-transplant, defined by expression of CXCL10, TNFSF10, TNFSF13B, CCL8 and ICAM1, consistent with a role in recruiting and activating recipient-derived B and T cells. Collectively, our findings define donor- and recipient-derived immune programs that distinguish living from deceased donor allografts, and shape early post-transplant immune responses in delayed graft function.
中文摘要:肾移植术后移植物功能延迟恢复与急性排斥反应发生率升高和长期结局较差相关。由于与热缺血和冷缺血时间延长相关的缺血再灌注损伤增加,其在接受死亡后捐献供肾的受者中比在接受活体供肾的受者中显著更常见。尽管特定免疫细胞群体与缺血再灌注损伤和移植物功能延迟恢复相关,但区分死亡后捐献与活体供者移植的精确细胞回路,以及参与早期免疫应答的供者和受者来源免疫程序,尚未在细胞分辨率上得到明确。为此,我们使用单细胞RNA测序,比较了20例活体供肾和6例死亡后捐献供肾的移植前免疫景观,并通过空间转录组学评估了另外2例死亡后捐献供者样本。随后,我们使用固定单细胞RNA谱分析,在8对配对的移植前和移植后同种异体移植物(共16份样本)中检查了时间性免疫变化,这些样本来自发生移植物功能延迟恢复的死亡后捐献肾移植受者。死亡后捐献供者同种异体移植物具有供者来源的驻留巨噬细胞,其趋化因子、细胞因子和抗原提呈基因表达降低,但自噬和泛素化相关转录本增加。这些巨噬细胞在移植后持续存在,并在空间上位于可与多种实质细胞群体相互作用的位置。在来自死亡后捐献供者的移植前和移植早期肾脏中,观察到表达双调蛋白的NK细胞以及表达TIGIT和KLRC1(NKG2A)的CD8+ T细胞减少,同时伴有表达KLRK1(NKG2D)的CD8+ T细胞富集和促炎特征。值得注意的是,移植后早期出现了一个转录上独特的、干扰素刺激的、受者来源的巨噬细胞群体,其以CXCL10、TNFSF10、TNFSF13B、CCL8和ICAM1表达为特征,与在募集和激活受者来源B细胞和T细胞中的作用一致。总体而言,我们的发现定义了供者和受者来源的免疫程序,这些程序可区分活体与死亡后捐献供者同种异体移植物,并塑造移植物功能延迟恢复中的移植后早期免疫应答。
3遗传性肾病/囊性 (1篇)
基础研究 (1篇)
Autosomal dominant polycystic kidney disease (ADPKD) is characterized by the slow, progressive formation of fluid-filled cysts within the kidneys, ultimately leading to kidney failure. Despite being the most common genetic kidney disease, therapies for ADPKD are limited. Ureteric bud (UB) organoids derived from human induced pluripotent stem cells (hiPSC) have been developed to model ADPKD. Here, we describe a protocol to generate UB organoids in large-scale suspension culture amenable to drug discovery. Day 12 'nephron' organoids derived from wildtype and PKD2-deficient hiPSC lines were dissociated into single cells and exposed to UB-propagating growth conditions in suspension culture, leading to formation of organoids with UB-like identity (UB organoids). Wildtype and cyst-forming PKD2-deficient UB organoids were characterized by immunohistochemistry, RT-qPCR and single-cell RNA-sequencing. Compound screening for cyst reduction was performed over a ten-day period, with cyst number and diameter quantified from brightfield images. UB organoids generated by our protocol are readily scalable, yielding up to 2000 organoids from approximately 50 nephron organoids within seven days. They exhibit tubular extension alongside the expression of UB-specific markers, including AQP2, WNT9B, and KRT8. PKD2-deficient UB organoids initiate cystogenesis within seven days, achieving very high cyst-forming efficiency by about 20 days. The cysts express ADPKD markers and respond to cyst-reducing compounds, including the Bromodomain inhibitor JQ1 and the NF-κB inhibitor QNZ, but not tolvaptan, consistent with low AVPR2 expression. To validate the platform as a drug discovery tool, we screened a small-molecule library and identified M1, a putative Toll-like receptor 4 (TLR4) antagonist, that reduces cyst size. Consistent with TLR4-driven cystogenesis, the investigational TLR4 inhibitor TAK-242 reduced, whereas lipopolysaccharide increased, cyst formation. We have developed a scalable method to generate cystic UB organoids, providing a simple and efficient platform for ADPKD drug discovery.
中文摘要:常染色体显性多囊肾病(ADPKD)的特征是肾脏内缓慢、进行性地形成充满液体的囊肿,最终导致肾衰竭。尽管它是最常见的遗传性肾脏疾病,但ADPKD的治疗方法仍然有限。源自人诱导多能干细胞(hiPSC)的输尿管芽(UB)类器官已被开发用于模拟ADPKD。在此,我们描述了一种在大规模悬浮培养中生成UB类器官、适用于药物发现的方案。将源自野生型和PKD2缺陷hiPSC系的第12天「肾单位」类器官解离为单细胞,并在悬浮培养中暴露于促UB增殖的生长条件,从而形成具有UB样特征的类器官(UB类器官)。通过免疫组织化学、RT-qPCR和单细胞RNA测序对野生型和形成囊肿的PKD2缺陷UB类器官进行了表征。在十天期间进行减少囊肿的化合物筛选,并从明场图像中量化囊肿数量和直径。该方案生成的UB类器官易于放大,在七天内可由约50个肾单位类器官产生多达2000个类器官。它们表现出管状延伸,同时表达UB特异性标志物,包括AQP2、WNT9B和KRT8。PKD2缺陷UB类器官在七天内启动囊肿发生,并在约20天时达到非常高的成囊效率。囊肿表达ADPKD标志物,并对减少囊肿的化合物产生反应,包括溴结构域抑制剂JQ1和NF-κB抑制剂QNZ,但对托伐普坦无反应,这与AVPR2低表达一致。为验证该平台作为药物发现工具的价值,我们筛选了一个小分子库,并鉴定出M1,一种推测的Toll样受体4(TLR4)拮抗剂,可减小囊肿大小。与TLR4驱动的囊肿发生一致,研究性TLR4抑制剂TAK-242减少了囊肿形成,而脂多糖则增加了囊肿形成。我们开发了一种可放大的方法来生成囊性UB类器官,为ADPKD药物发现提供了一个简单而高效的平台。
4肾小球疾病 (1篇)
临床研究 (1篇)
Circulating anti-nephrin autoantibodies are being increasingly recognized in autoimmune podocytopathies, particularly minimal change disease (MCD) and focal segmental glomerulosclerosis (FSGS). However, circulating anti-nephrin reactivity is often low, and currently available assays differ substantially in design, antigen production, and analytical performance. This methodological heterogeneity highlights the need for standardized and quantitative assays for clinical application. Recombinant human nephrin ectodomain-coated magnetic microparticles were used to establish an automated chemiluminescence immunoassay (CLIA). Serum anti-nephrin IgG was measured in 121 children with biopsy-confirmed MCD (n=103) or primary FSGS (n=18), together with disease controls (genetically confirmed MCD/FSGS, IgA nephropathy, IgA vasculitis with nephritis, lupus nephritis, and ANCA-associated glomerulonephritis) and healthy individuals. Samples were tested in parallel by immunoprecipitation-Western blot (IP-WB). Antigen inhibition assays and cohort-based clinical analyses were performed. The CLIA met predefined analytical performance criteria and showed substantial agreement with IP-WB, with an overall concordance of 86.8% and Cohen's kappa coefficient of 0.714. CLIA detected anti-nephrin IgG more frequently than IP-WB in patients with MCD or FSGS (41.3% vs. 28.1%), including additional low-level positive samples. Antigen inhibition assays showed dose-dependent inhibition in CLIA-positive samples. Among patients with baseline nephrotic-range proteinuria, antibody positivity was associated with greater proteinuria, lower serum albumin, and steroid-sensitive nephrotic syndrome. Patients with elevated anti-nephrin IgG levels had significantly shorter relapse-free survival. During complete remission, anti-nephrin IgG positivity was associated with relapse within three months, with relapse risk increasing according to antibody level. Together, our automated CLIA may help move anti-nephrin IgG testing from specialized research workflows toward standardized clinical application, supporting future use in disease stratification and longitudinal monitoring.
中文摘要:循环抗nephrin自身抗体在自身免疫性足细胞病,尤其是微小病变肾病(MCD)和局灶节段性肾小球硬化(FSGS)中正日益受到认识。然而,循环抗nephrin反应性通常较低,且目前可用的检测方法在设计、抗原制备和分析性能方面差异很大。这种方法学异质性凸显了建立标准化定量检测方法以供临床应用的必要性。采用重组人nephrin胞外域包被的磁性微粒建立了自动化化学发光免疫分析(CLIA)。在121例经活检确诊的MCD(n=103)或原发性FSGS(n=18)患儿中检测了血清抗nephrin IgG,同时检测了疾病对照(经基因确诊的MCD/FSGS、IgA肾病、伴肾炎的IgA血管炎、狼疮性肾炎和ANCA相关性肾小球肾炎)及健康个体。样本通过免疫沉淀-Western blot(IP-WB)平行检测。进行了抗原抑制试验和基于队列的临床分析。CLIA符合预设分析性能标准,并与IP-WB显示高度一致,总体一致率为86.8%,Cohen's kappa系数为0.714。在MCD或FSGS患者中,CLIA比IP-WB更频繁地检测到抗nephrin IgG(41.3% vs. 28.1%),包括额外的低水平阳性样本。抗原抑制试验显示CLIA阳性样本呈剂量依赖性抑制。在基线肾病范围蛋白尿患者中,抗体阳性与更高的蛋白尿、更低的血清白蛋白和激素敏感性肾病综合征相关。抗nephrin IgG水平升高的患者无复发生存期显著更短。在完全缓解期间,抗nephrin IgG阳性与3个月内复发相关,且复发风险随抗体水平升高而增加。总之,我们的自动化CLIA可能有助于推动抗nephrin IgG检测从专门的研究工作流程走向标准化临床应用,支持未来用于疾病分层和纵向监测。
5急性肾损伤 AKI (1篇)
基础研究 (1篇)
Sex influences susceptibility, recovery, and long-term outcomes after acute kidney injury (AKI) in humans. Rodent models have been invaluable for elucidating AKI mechanisms. However, most studies have focused on males, assuming direct applicability to females, an assumption that remains largely untested. In males, the transcription factor SOX9 regulates injury-associated proximal tubule cell states, promoting adaptive repair and survival in the early phase while contributing to fibrosis in later phases. Given the well-described role of SOX9 in sex determination during development and its emerging importance in AKI, we investigated whether it mediates sex-specific tubular responses in the adult kidney. We first optimized differential ischemic and cisplatin conditions in males and females to generate injury-matched models. We then used these models to ask whether proximal tubular cell responses, particularly Sox9 upregulation, are sex dependent. Tubule-specific knockout models of Sox9, Sox4, Sox11, Vgf, Zfp24, and the androgen receptor (Ar), along with gonadectomy and hormone replacement studies, combined with gene and protein analyses, were used to define regulatory networks. Under injury-matched conditions, biomarkers such as NGAL and KIM1 were equally induced in the kidneys of both sexes. However, Sox9 and its downstream target Vgf showed markedly blunted induction in females. Consistent with male-specific Sox9 induction, the upstream transcription factor Zfp24 was dephosphorylated and activated only in males. Deletion of Sox9, Zfp24, or Vgf worsened injury in males but not in females. In contrast, Sox4 and Sox11 were equally upregulated and protective in both sexes. Castration or proximal tubule-specific deletion of Ar in males abolished Sox9 induction, establishing a testosterone-dependent regulatory axis. Our findings define a hormone-driven, male-specific tubular repair program and demonstrate that injury and recovery pathways differ fundamentally between sexes, underscoring the need for sex-inclusive therapeutic strategies for AKI.
中文摘要:性别影响人类急性肾损伤(AKI)后的易感性、恢复和长期结局。啮齿动物模型对于阐明 AKI 机制非常宝贵。然而,大多数研究集中于雄性,并假设其可直接适用于雌性,而这一假设在很大程度上仍未经验证。在雄性中,转录因子 SOX9 调控损伤相关的近端小管细胞状态,在早期促进适应性修复和存活,而在后期促进纤维化。鉴于 SOX9 在发育过程中性别决定中的已知作用及其在 AKI 中日益重要,我们研究它是否介导成年肾脏中性别特异性的小管反应。我们首先分别优化雄性和雌性的缺血与顺铂条件,以建立损伤匹配模型。然后我们使用这些模型来探究近端小管细胞反应,特别是 Sox9 上调,是否具有性别依赖性。我们使用 Sox9、Sox4、Sox11、Vgf、Zfp24 和雄激素受体(Ar)的小管特异性敲除模型,以及性腺切除和激素替代研究,结合基因和蛋白分析,来定义调控网络。在损伤匹配条件下,NGAL 和 KIM1 等生物标志物在两性肾脏中被同等诱导。然而,Sox9 及其下游靶点 Vgf 在雌性中的诱导显著减弱。与雄性特异性 Sox9 诱导一致,上游转录因子 Zfp24 仅在雄性中去磷酸化并被激活。敲除 Sox9、Zfp24 或 Vgf 会加重雄性损伤,但不会加重雌性损伤。相反,Sox4 和 Sox11 在两性中同等上调并具有保护作用。在雄性中,去势或近端小管特异性敲除 Ar 消除了 Sox9 诱导,从而确立了一个睾酮依赖性调控轴。我们的发现定义了一个激素驱动的、雄性特异性小管修复程序,并证明损伤和恢复通路在两性之间存在根本差异,强调需要针对 AKI 制定纳入两性的治疗策略。
6糖尿病肾病 (1篇)
临床研究 (1篇)
To establish a comprehensive theranostic framework for early-stage diabetic kidney disease (DKD) by validating serum S100A8/A9 as a highly sensitive diagnostic biomarker and exploring therapeutic strategies targeting the S100A9/transmembrane protein 24 (TMEM24) signaling axis to restore podocyte autophagy. A clinical cohort and machine learning algorithms (Random Forest/Neural Networks) were employed to evaluate the diagnostic performance of S100A8/A9. In vivo (db/db mice) and in vitro (HG-stimulated podocytes) models were used to investigate the molecular mechanisms. Co-IP-LC/MS and protein truncation assays identified S100A9-interacting partners. Structure-based virtual screening was utilized to identify Shikonin as a novel TMEM24-targeting ligand, and its renoprotective effects were rigorously validated. Serum S100A8/A9 levels were significantly elevated in early DKD, outperforming conventional markers in machine learning models (AUC up to 0.978). Mechanistically, S100A9 interacts with Transmembrane Protein 24 (TMEM24) through its SMP and C2 domains, hyperactivating the PI3K/AKT/mTOR pathway and impairing podocyte autophagy. Shikonin, identified through virtual screening, demonstrated a strong binding affinity for TMEM24. Administration of Shikonin dose-dependently inhibited the TMEM24-mediated PI3K/AKT/mTORC1 signaling, thereby restoring autophagic flux and ameliorating podocyte injury, glomerular basement membrane thickening, and renal fibrosis. This study defines S100A8/A9 as a pivotal biomarker and therapeutic target, offering a theranostic strategy where Shikonin serves as a potent agent to ameliorate DKD progression by targeting the TMEM24-autophagy axis.
中文摘要:为建立早期糖尿病肾病(DKD)的综合诊疗框架,验证血清S100A8/A9作为高灵敏度诊断生物标志物,并探索靶向S100A9/跨膜蛋白24(TMEM24)信号轴以恢复足细胞自噬的治疗策略。采用临床队列和机器学习算法(随机森林/神经网络)评估S100A8/A9的诊断性能。使用体内(db/db小鼠)和体外(高糖刺激的足细胞)模型研究分子机制。通过免疫共沉淀-液相色谱/质谱联用(Co-IP-LC/MS)和蛋白截短实验鉴定S100A9相互作用伙伴。利用基于结构的虚拟筛选鉴定出紫草素(Shikonin)作为一种新型TMEM24靶向配体,并严格验证其肾脏保护作用。早期DKD患者血清S100A8/A9水平显著升高,在机器学习模型中优于传统标志物(AUC高达0.978)。机制上,S100A9通过其SMP和C2结构域与跨膜蛋白24(TMEM24)相互作用,过度激活PI3K/AKT/mTOR通路并损害足细胞自噬。通过虚拟筛选鉴定的紫草素对TMEM24表现出强结合亲和力。给予紫草素剂量依赖性抑制TMEM24介导的PI3K/AKT/mTORC1信号,从而恢复自噬流并改善足细胞损伤、肾小球基底膜增厚和肾纤维化。本研究将S100A8/A9定义为关键生物标志物和治疗靶点,提供了一种诊疗策略,其中紫草素作为有效药物通过靶向TMEM24-自噬轴改善DKD进展。